Literature DB >> 20135140

Reduced concentrations of angiogenesis-related factors in vitreous after vitrectomy in patients with proliferative diabetic retinopathy.

Shigeo Yoshida1, Keijiro Ishikawa, Tokiko Matsumoto, Ayako Yoshida, Tatsuro Ishibashi, Toshihiro Kono.   

Abstract

BACKGROUND: The purpose of this study was to determine whether vitrectomy alters the angiogenic profile in the vitreous of eyes with proliferative diabetic retinopathy (PDR).
METHODS: We measured the levels of angiopoietin-2, HGF, bFGF, PDGF, TIMP-1, and TIMP-2 by sandwich enzyme linked immunosorbent assay (ELISA) in vitreous samples from 27 eyes of 26 patients with PDR before pars plana vitrectomy (without IOL implantation) and in 12 fluid samples from 12 patients with PDR obtained during an IOL implantation 3.5 to 9 (mean 4.9) months after an earlier vitrectomy. The levels of these factors were also measured in 12 vitreous samples obtained from 12 eyes that had undergone epiretinal membrane (ERM) or macular hole (MH) surgeries.
RESULTS: The mean vitreous levels of both angiopietin-2 (103 pg/ml) and HGF (1091 pg/ml) in the sample from eyes with PDR collected at the time of the IOL implantation were significantly lower than in those collected before the vitrectomy (P < 0.01). On the other hand, the changes in the levels of TIMP-1 and TIMP-2 were both not significant after vitrectomy.
CONCLUSION: The significant decrease of angiopietin-2 and HGF in the vitreous fluid after vitrectomy suggests that vitrectomy shifts the eye towards an anti-angiogenic environment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20135140     DOI: 10.1007/s00417-010-1301-5

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  25 in total

1.  Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy.

Authors:  Daisuke Watanabe; Kiyoshi Suzuma; Izumi Suzuma; Hirokazu Ohashi; Tomonari Ojima; Masafumi Kurimoto; Tomoaki Murakami; Tetsushi Kimura; Hitoshi Takagi
Journal:  Am J Ophthalmol       Date:  2005-03       Impact factor: 5.258

2.  Ocular oxygen consumption during vitreoperfusion in the cat.

Authors:  N P Blair
Journal:  Trans Am Ophthalmol Soc       Date:  2000

3.  Long-term diabetic vitrectomy results. Report of 10 year follow-up.

Authors:  G W Blankenship; R Machemer
Journal:  Ophthalmology       Date:  1985-04       Impact factor: 12.079

4.  Soluble TNF receptors in vitreoretinal proliferative disease.

Authors:  G A Limb; R D Hollifield; L Webster; D G Charteris; A H Chignell
Journal:  Invest Ophthalmol Vis Sci       Date:  2001-06       Impact factor: 4.799

5.  Expression of thrombospondin-1 in ischemia-induced retinal neovascularization.

Authors:  K Suzuma; H Takagi; A Otani; H Oh; Y Honda
Journal:  Am J Pathol       Date:  1999-02       Impact factor: 4.307

6.  Role of NF-kappaB-mediated interleukin-8 expression in intraocular neovascularization.

Authors:  A Yoshida; S Yoshida; A K Khalil; T Ishibashi; H Inomata
Journal:  Invest Ophthalmol Vis Sci       Date:  1998-06       Impact factor: 4.799

7.  Endocapsular hypopyon: a clinical sign of localized endophthalmitis.

Authors:  E Stefansson; L M Cobo; A N Carlson; J L Kesler
Journal:  Ophthalmic Surg       Date:  1990-03

8.  Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene.

Authors:  Selma Pennacchietti; Paolo Michieli; Maria Galluzzo; Massimiliano Mazzone; Silvia Giordano; Paolo M Comoglio
Journal:  Cancer Cell       Date:  2003-04       Impact factor: 31.743

Review 9.  Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy.

Authors:  Rafael Simó; Esther Carrasco; Marta García-Ramírez; Cristina Hernández
Journal:  Curr Diabetes Rev       Date:  2006-02

10.  Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.

Authors:  L P Aiello; R L Avery; P G Arrigg; B A Keyt; H D Jampel; S T Shah; L R Pasquale; H Thieme; M A Iwamoto; J E Park
Journal:  N Engl J Med       Date:  1994-12-01       Impact factor: 91.245

View more
  6 in total

1.  Vitreous TIMP-1 levels associate with neovascularization and TGF-β2 levels but not with fibrosis in the clinical course of proliferative diabetic retinopathy.

Authors:  Rob J Van Geest; Ingeborg Klaassen; Sarit Y Lesnik-Oberstein; H Stevie Tan; Marco Mura; Roel Goldschmeding; Cornelis J F Van Noorden; Reinier O Schlingemann
Journal:  J Cell Commun Signal       Date:  2012-10-02       Impact factor: 5.782

Review 2.  Periostin in vitreoretinal diseases.

Authors:  Shigeo Yoshida; Takahito Nakama; Keijiro Ishikawa; Shintaro Nakao; Koh-Hei Sonoda; Tatsuro Ishibashi
Journal:  Cell Mol Life Sci       Date:  2017-09-14       Impact factor: 9.261

3.  Differential association of elevated inflammatory cytokines with postoperative fibrous proliferation and neovascularization after unsuccessful vitrectomy in eyes with proliferative diabetic retinopathy.

Authors:  Shigeo Yoshida; Yoshiyuki Kobayashi; Shintaro Nakao; Yukio Sassa; Toshio Hisatomi; Yasuhiro Ikeda; Yuji Oshima; Toshihiro Kono; Tatsuro Ishibashi; Koh-Hei Sonoda
Journal:  Clin Ophthalmol       Date:  2017-09-19

4.  Comparison of gene expression profile of epiretinal membranes obtained from eyes with proliferative vitreoretinopathy to that of secondary epiretinal membranes.

Authors:  Ryo Asato; Shigeo Yoshida; Atsushi Ogura; Takahito Nakama; Keijiro Ishikawa; Shintaro Nakao; Yukio Sassa; Hiroshi Enaida; Yuji Oshima; Kazuho Ikeo; Takashi Gojobori; Toshihiro Kono; Tatsuro Ishibashi
Journal:  PLoS One       Date:  2013-01-23       Impact factor: 3.240

Review 5.  Candidate genes for proliferative diabetic retinopathy.

Authors:  Daniel Petrovič
Journal:  Biomed Res Int       Date:  2013-08-27       Impact factor: 3.411

6.  Functional and molecular characterization of ex vivo cultured epiretinal membrane cells from human proliferative diabetic retinopathy.

Authors:  Zoltán Veréb; Xhevat Lumi; Sofija Andjelic; Mojca Globocnik-Petrovic; Mojca Urbancic; Marko Hawlina; Andrea Facskó; Goran Petrovski
Journal:  Biomed Res Int       Date:  2013-10-01       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.